705 related articles for article (PubMed ID: 28476121)
21. An updated systematic review of the cost-effectiveness of therapies for metastatic breast cancer.
Gogate A; Rotter JS; Trogdon JG; Meng K; Baggett CD; Reeder-Hayes KE; Wheeler SB
Breast Cancer Res Treat; 2019 Apr; 174(2):343-355. PubMed ID: 30603995
[TBL] [Abstract][Full Text] [Related]
22. Menopausal hormone therapy use in relation to breast cancer incidence in 11 European countries.
Antoine C; Ameye L; Paesmans M; de Azambuja E; Rozenberg S
Maturitas; 2016 Feb; 84():81-8. PubMed ID: 26654400
[TBL] [Abstract][Full Text] [Related]
23. Cost-Effectiveness of Treatment Options for Neuropathic Pain: a Systematic Review.
Ruiz-Negrón N; Menon J; King JB; Ma J; Bellows BK
Pharmacoeconomics; 2019 May; 37(5):669-688. PubMed ID: 30637713
[TBL] [Abstract][Full Text] [Related]
24. Menopausal hormone therapy (MHT): refining our understanding of MHT research, optimally applying results, and considering the future of MHT.
Anagnostis EA
J Pharm Pract; 2012 Jun; 25(3):324-30. PubMed ID: 22550160
[TBL] [Abstract][Full Text] [Related]
25. Systematic review and cost-effectiveness evaluation of 'pill-in-the-pocket' strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy.
Saborido CM; Hockenhull J; Bagust A; Boland A; Dickson R; Todd D
Health Technol Assess; 2010 Jun; 14(31):iii-iv, 1-75. PubMed ID: 20569652
[TBL] [Abstract][Full Text] [Related]
26. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of hormone replacement therapy for menopausal symptoms in the UK.
Lekander I; Borgström F; Ström O; Zethraeus N; Kanis JA
Menopause Int; 2009 Mar; 15(1):19-25. PubMed ID: 19237618
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of raloxifene and hormone replacement therapy in postmenopausal women: impact of breast cancer risk.
Armstrong K; Chen TM; Albert D; Randall TC; Schwartz JS
Obstet Gynecol; 2001 Dec; 98(6):996-1003. PubMed ID: 11755544
[TBL] [Abstract][Full Text] [Related]
29. An update on menopausal hormone replacement therapy in women and cardiovascular disease.
Valdiviezo C; Lawson S; Ouyang P
Curr Opin Endocrinol Diabetes Obes; 2013 Apr; 20(2):148-55. PubMed ID: 23422240
[TBL] [Abstract][Full Text] [Related]
30. The Women's Health Initiative trial and related studies: 10 years later: a clinician's view.
Gurney EP; Nachtigall MJ; Nachtigall LE; Naftolin F
J Steroid Biochem Mol Biol; 2014 Jul; 142():4-11. PubMed ID: 24172877
[TBL] [Abstract][Full Text] [Related]
31. Recent epidemiological evidence relevant to the clinical management of the menopause.
Shapiro S
Climacteric; 2007 Oct; 10 Suppl 2():2-15. PubMed ID: 17882666
[TBL] [Abstract][Full Text] [Related]
32. Cost effectiveness of hormone therapy in women at high risks of fracture in Sweden, the US and the UK--results based on the Women's Health Initiative randomised controlled trial.
Lekander I; Borgström F; Ström O; Zethraeus N; Kanis JA
Bone; 2008 Feb; 42(2):294-306. PubMed ID: 18053789
[TBL] [Abstract][Full Text] [Related]
33. The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model.
Crathorne L; Huxley N; Haasova M; Snowsill T; Jones-Hughes T; Hoyle M; Briscoe S; Coelho H; Long L; Medina-Lara A; Mujica-Mota R; Napier M; Hyde C
Health Technol Assess; 2016 Feb; 20(13):1-588, v-vi. PubMed ID: 26907163
[TBL] [Abstract][Full Text] [Related]
34. Best practices in care for menopausal patients: 16 years after the Women's Health Initiative.
DeNeui T; Berg J; Howson A
J Am Assoc Nurse Pract; 2019 Jul; 31(7):420-427. PubMed ID: 30908403
[TBL] [Abstract][Full Text] [Related]
35. Hormone replacement therapy in the post-Women's Health Initiative era. Report a a meeting held in Funchal, Madeira, February 24-25, 2003.
Burger H
Climacteric; 2003 May; 6 Suppl 1():11-36. PubMed ID: 12945798
[TBL] [Abstract][Full Text] [Related]
36. Cost effectiveness of fecal DNA screening for colorectal cancer: a systematic review and quality appraisal of the literature.
Skally M; Hanly P; Sharp L
Appl Health Econ Health Policy; 2013 Jun; 11(3):181-92. PubMed ID: 23549792
[TBL] [Abstract][Full Text] [Related]
37. Menopausal hormone therapy for the primary prevention of chronic conditions: a systematic review to update the U.S. Preventive Services Task Force recommendations.
Nelson HD; Walker M; Zakher B; Mitchell J
Ann Intern Med; 2012 Jul; 157(2):104-13. PubMed ID: 22786830
[TBL] [Abstract][Full Text] [Related]
38. The clinical effectiveness and cost-effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation.
Loveman E; Jones J; Hartwell D; Bird A; Harris P; Welch K; Clegg A
Health Technol Assess; 2010 Mar; 14(19):1-204. PubMed ID: 20356561
[TBL] [Abstract][Full Text] [Related]
39. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
